GlassScriptPhysician profile
Andrew Thomas Brooks
NPI 1376519561
$6,892.88
in general payments reported to CMS, 2019-2025
18 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $245 · 2021: $947 · 2022: $383 · 2023: $187 · 2024: $4,436 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720 · Travel and Lodging: $2,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.87 |
| Travel and Lodging | $2,014.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $5,054.36 | 2021-2024 | Rosa, Persona |
| Ferring Pharmaceuticals INC. | $1,078.77 | 2019-2023 | Euflexxa |
| Bioventus LLC | $119.87 | 2019-2025 | Durolane, Xcell, Durolane |
| Stryker Corporation | $108.74 | 2019-2024 | Insignia, Mako |
| Heraeus Medical, LLC. | $83.27 | 2022-2024 | Palacos |
| Amgen INC. | $76.84 | 2022-2023 | Otezla, Enbrel |
| Sanofi-Aventis U.S. LLC | $75.44 | 2019-2023 | |
| Janssen Biotech, INC. | $66.58 | 2022-2025 | Tremfya, Erleada |
| Novartis Pharmaceuticals Corporation | $39.77 | 2025 | |
| Ethicon US, LLC | $25.22 | 2022 | |
| Heron Therapeutics, INC. | $23.99 | 2023 | Zynrelef |
| Pacira Therapeutics, INC. | $23.23 | 2020 | |
| Depuy Synthes Sales INC. | $22.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2025 | Caplyta |
| Aurinia Pharma U.S., INC. | $21.94 | 2024 | Lupkynis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.60 | 2024 | Benlysta |
| Kci USA, INC. | $17.14 | 2022 | |
| Abbvie INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.